Plain-English translation of NCT06855277 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new radioactive medication called combined with hormone therapy drugs to treat advanced prostate cancer that has stopped responding to earlier hormone treatments. Researchers want to see if this combination works better than the current standard treatments—which might be a switch to a different hormone therapy, chemotherapy, or another radioactive treatment. The study will enroll about 940 men across multiple hospitals.
Advanced prostate cancer often becomes resistant to the first hormone therapies doctors try, leaving patients with limited options. This trial exists to find out whether this new radioactive medication, especially when combined with hormone therapy, can help men live longer without their cancer getting worse.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to receive either the new radioactive treatment () with or without hormone therapy, or one of the standard treatments your doctor chooses (a different hormone therapy, chemotherapy, or another radioactive treatment). You will receive up to 6 intravenous infusions of the medication spaced over time, with regular safety check-ups and scans to monitor how you are doing. The trial takes place across multiple hospitals in the United States and other countries.
AI-generated summary from trial data · Aug 19, 2026 · Not medical advice
United States